Skip to main content

Healthy Adult Male and Female Volunteers

5
Pipeline Programs
6
Companies
5
Clinical Trials
4 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
5
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Eddingpharm
EddingpharmChina - Shanghai
1 program
1
EDP167Phase 11 trial
Active Trials
NCT07412080Completed40Est. Dec 2025
ENYO Pharma
ENYO PharmaFrance - Lyon
1 program
1
EYP651/Vonafexor low dosePhase 11 trial
Active Trials
NCT07251153Recruiting40Est. Oct 2026
Menarini
MenariniGermany - Dresden
1 program
1
Torasemide tablet 10 mgPhase 11 trial
Active Trials
NCT07201584Recruiting26Est. Apr 2026
Berlin-Chemie
Berlin-ChemieGermany - Berlin
1 program
1
Torasemide tablet 10 mgPhase 1
NeuroDawn Pharmaceutical
1 program
1
Y-4 tablesPhase 11 trial
Active Trials
NCT06935682Recruiting36Est. Jun 2025
Centessa Pharmaceuticals
1 program
ORX489 TabletsPHASE_11 trial
Active Trials
NCT07413666Recruiting212Est. Jun 2027

Trial Timeline

Clinical trial activity over time

2025
2026
2027
Centessa PharmaceuticalsORX489 Tablets
ENYO PharmaEYP651/Vonafexor low dose
MenariniTorasemide tablet 10 mg
EddingpharmEDP167
NeuroDawn PharmaceuticalY-4 tables

Clinical Trials (5)

Total enrollment: 354 patients across 5 trials

NCT07413666Centessa PharmaceuticalsORX489 Tablets

A Study of ORX489 in Healthy Adult Participants, Aged 18 to 60 Years

Start: Feb 2026Est. completion: Jun 2027212 patients
Phase 1Recruiting
NCT07251153ENYO PharmaEYP651/Vonafexor low dose

Pharmacokinetic Comparison of Vonafexor Acid and Its Lysine Salt and Evaluation of Potential Drug-Drug Interactions

Start: Oct 2025Est. completion: Oct 202640 patients
Phase 1Recruiting
NCT07201584MenariniTorasemide tablet 10 mg

A Comparative Bioavailability Study of Two Torasemide 10 mg Tablets Formulations in Healthy Adult Participants Under Fasting Conditions:

Start: Sep 2025Est. completion: Apr 202626 patients
Phase 1Recruiting
NCT07412080EddingpharmEDP167

EDP167 in Healthy Volunteers and Subjects With Mild Dyslipidemia

Start: Jul 2025Est. completion: Dec 202540 patients
Phase 1Completed
NCT06935682NeuroDawn PharmaceuticalY-4 tables

Safety and Pharmacokinetics of Y-4 Tablets in Healthy Subjects

Start: Jan 2025Est. completion: Jun 202536 patients
Phase 1Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 actively recruiting trials targeting 354 patients
6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.